Last reviewed · How we verify
NCT06678165
A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia
EARLY_PHASE1 trial testing YOLT-204 in Transfusion Dependent Beta Thalassemia in 3 participants. Not yet recruiting.
1 June 2026
Quick facts
| Lead sponsor | First Affiliated Hospital of Guangxi Medical University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 31 December 2024 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- YOLT-204 — full drug profile →
Conditions studied
- Transfusion Dependent Beta Thalassemia — all drugs for Transfusion Dependent Beta Thalassemia →
Sponsor
First Affiliated Hospital of Guangxi Medical University
Who can join
Adults 18 to 35, any sex, with Transfusion Dependent Beta Thalassemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a single-arm, open-label, dose-escalation trial, planning to enroll 3-9 patients with transfusion-dependent β-thalassemia, aimed at assessing the safety and tolerability of a single-dose of YOLT-204 in patients with transfusion-dependent β-thalassemia; to preliminarily evaluate the impact of a single -dose of YOLT-204 on the levels of fetal hemoglobin in the plasma
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06678165
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of YOLT-204
Trials testing the same drug.
- NCT07190001 — YOLT-204 in Patients With Hemoglobinopathies · EARLY_PHASE1 · not yet recruiting
Other recruiting trials for Transfusion Dependent Beta Thalassemia
Currently open trials in the same condition.
- NCT07292259 — Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia · Phase 2 · recruiting
Other First Affiliated Hospital of Guangxi Medical University trials
Trials by the same sponsor.
- NCT07459296 — Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · Phase 3 · recruiting
- NCT07342322 — A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatial · Phase 2 · not yet recruiting
- NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
- NCT07132008 — Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer · Phase 3 · not yet recruiting
- NCT07074444 — Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06678165 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Guangxi Medical University
- Last refreshed: 7 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06678165.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing